Download MendeleyDiscovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
Madar, D.J., Kopecka, H., Pireh, D., Yong, H., Pei, Z., Li, X., Wiedeman, P.E., Djuric, S.W., Von Geldern, T.W., Fickes, M.G., Bhagavatula, L., McDermott, T., Wittenberger, S., Richards, S.J., Longenecker, K.L., Stewart, K.D., Lubben, T.H., Ballaron, S.J., Stashko, M.A., Long, M.A., Wells, H., Zinker, B.A., Mika, A.K., Beno, D.W., Kempf-Grote, A.J., Polakowski, J., Segreti, J., Reinhart, G.A., Fryer, R.M., Sham, H.L., Trevillyan, J.M.(2006) J Med Chem 49: 6416-6420
- PubMed: 17034148
- DOI: https://doi.org/10.1021/jm060777o
- Primary Citation of Related Structures:
2I03 - PubMed Abstract:
Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised to be the next major drug class for the treatment of type 2 diabetes. Structure-activity studies of substitutions at the C5 position of the 2-cyanopyrrolidide warhead led to the discovery of potent inhibitors of DPP-IV that lack activity against DPP8 and DPP9. Further modification led to an extremely potent (Ki(DPP)(-)(IV) = 1.0 nM) and selective (Ki(DPP8) > 30 microM; Ki(DPP9) > 30 microM) clinical candidate, ABT-279, that is orally available, efficacious, and remarkably safe in preclinical safety studies.
Organizational Affiliation:
Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064-6001, USA. david.madar@abbott.com
